Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 5:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 1,708 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Human Immunodeficiency Virus Infection (HIV) Clear all
Completed Phase 2 Interventional

Immune Restoration by Lipoic Acid in AIDS

NCT00033176
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
Alpha Lipoic Acid
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
2
States / cities
San Francisco, California • San Jose, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 26, 2026, 5:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pharmacy-based Pre-exposure Prophylaxis

NCT04393935
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Pharmacy Delivered PrEP Intervention
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 26, 2026, 5:30 AM EDT
Completed Phase 3 Interventional

A Randomized, Double-Blind, Comparative Study of Azithromycin Versus Clarithromycin in Combination With Ethambutol for the Treatment of Disseminated Mycobacterium Avium Complex (MAC) Infection in AIDs Patients

NCT00002140
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Ethambutol hydrochloride, Clarithromycin, Azithromycin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
24
States / cities
Berkeley, California • Mill Valley, California • Oakland, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 26, 2026, 5:30 AM EDT
Completed Phase 3 Interventional Results available

Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1)

NCT02429791
View directory record Official record
Conditions
HIV Infections
Interventions
DTG 50 mg, RPV 25 mg, CAR
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
13
States / cities
Long Beach, California • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 26, 2026, 5:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Home Self-Testing for HIV to Increase HIV Testing Frequency in Men Who Have Sex With Men (The iTest Study)

NCT01161446
View directory record Official record
Conditions
HIV
Interventions
Home HIV self-testing with OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test, Home HIV self-testing with OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test
Behavioral · Device
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Oct 26, 2026, 5:30 AM EDT
Completed Phase 1 Interventional

A Pharmacokinetic and Tolerance Study of Oral Ganciclovir in HIV-Infected Children With Asymptomatic Cytomegalovirus Infection and Low CD4 Cell Counts or Quiescent Cytomegalovirus Disease

NCT00000805
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
14 Days to 20 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
18
States / cities
Los Angeles, California • Oakland, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 26, 2026, 5:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Being Responsible for Ourselves HIV Risk Reduction for Black MSM

NCT02561286
View directory record Official record
Conditions
Human Immunodeficiency Virus Infection (HIV), Sexually Transmitted Disease (STD)
Interventions
BRO HIV Risk Reduction Intervention, Health Promotion Intervention
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Male only
Enrollment
595 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 29, 2015 · Synced Oct 26, 2026, 5:30 AM EDT
Completed Phase 2 Interventional Results available

Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)

NCT01928927
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Telmisartan
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
11
States / cities
Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 26, 2026, 5:30 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

This Study Evaluates the ALPCO Syphilis-T and Syphilis-NT CLIA Kits for Detecting Syphilis Antibodies in Serum and Plasma. Samples From At-risk, HIV-positive, Pregnant, and Healthy Individuals Will Assess Assay Performance Versus Established Comparator Tests.

NCT07089836
View directory record Official record
Conditions
Treponema Pallidum, Treponema Pallidum Infection, Syphilis Infection, Serum, Plasma, Blooddraw, Sexually Transmitted Infection (STI)
Interventions
ALPCO Syphilis-T, ALPCO Syphilis-NT CLIA Kits
Device
Lead sponsor
American Laboratory Products Company
Industry
Eligibility
13 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
6
States / cities
Lancaster, California • Los Angeles, California • North Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 26, 2026, 5:30 AM EDT
Completed Phase 2 Interventional

A Study of WR 6026 in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in HIV-Infected Patients

NCT00000863
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Sitamaquine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
12
States / cities
Birmingham, Alabama • Honolulu, Hawaii • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 26, 2026, 5:30 AM EDT
Suspended Phase 1Phase 2 Interventional

Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1

NCT06071767
View directory record Official record
Conditions
HIV-1-infection
Interventions
ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62, MVA.tHIVconsv3, MVA.tHIVconsv4, Vesatolimod (VES), GS-5423, GS-2872, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
9
States / cities
San Diego, California • Atlanta, Georgia • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 26, 2026, 5:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study of a Dolutegravir Dispersible Tablet and Effect of Different Types of Water on the Dispersible Tablet in Healthy Volunteers

NCT02185300
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Dolutegravir Pediatric Granules, Dolutegravir Dispersible Tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 26, 2026, 5:30 AM EDT
Completed Phase 2 Interventional

The Safety and Effectiveness of FIAC in the Treatment of Cytomegalovirus (CMV) in Patients With AIDS

NCT00000981
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Fiacitabine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
4
States / cities
Birmingham, Alabama • San Diego, California • Bethesda, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2012 · Synced Oct 26, 2026, 5:30 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 HCV and HIV-1 Co-infection

NCT02480387
View directory record Official record
Conditions
Treatment of Hepatitis C
Interventions
Ledipasvir/Sofosbuvir FDC
Drug
Lead sponsor
Peter J. Ruane, M.D., Inc.
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Oct 26, 2026, 5:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Antacids on the Pharmacokinetics of Raltegravir

NCT00944307
View directory record Official record
Conditions
HIV Infections
Interventions
raltegravir, antacid
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 26, 2026, 5:30 AM EDT
Completed Phase 2 Interventional

A Study Comparing 4 Doses Of GW810781 Versus Placebo In HIV-Infected Patients

NCT00046332
View directory record Official record
Conditions
HIV Infections
Interventions
GW810781
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Oct 26, 2026, 5:30 AM EDT
Completed No phase listed Observational

Observation of HIV-Infected Children Receiving Protease Inhibitor and Reverse Transcriptase Inhibitor

NCT00001826
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 26, 2026, 5:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Pragmatic Clinical Trial of MyPEEPS Mobile to Improve HIV Prevention Behaviors in Diverse Adolescent MSM

NCT03167606
View directory record Official record
Conditions
HIV Infections
Interventions
MyPEEPS Mobile
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
13 Years to 18 Years · Male only
Enrollment
764 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
4
States / cities
Birmingham, Alabama • Chicago, Illinois • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 26, 2026, 5:30 AM EDT
Completed Phase 2 Interventional

Continued Antiretroviral Therapy With Abacavir, Amprenavir and Efavirenz

NCT00001758
View directory record Official record
Conditions
HIV Infection
Interventions
Abacavir, Amprenavir, Efavirenz
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 26, 2026, 5:30 AM EDT
Recruiting Phase 1Phase 2 Interventional

Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission

NCT02140255
View directory record Official record
Conditions
HIV Infection
Interventions
Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Nevirapine (NVP), Lopinavir/Ritonavir (LPV/r), Raltegravir (RAL), VRC01, Dolutegravir (DTG), VRC07-523LS
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 48 Hours
Enrollment
1,120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2031
U.S. locations
21
States / cities
La Jolla, California • Los Angeles, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 26, 2026, 5:30 AM EDT
Completed Phase 1 Interventional

A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 (rCD4) in Infants and Children Infected With or at Risk for HIV Infection

NCT00000984
View directory record Official record
Conditions
HIV Infections
Interventions
CD4 Antigens
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
San Francisco, California • Stanford, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 26, 2026, 5:30 AM EDT
Completed No phase listed Observational

Evaluation of Brain Lesions in HIV-infected Patients for Diagnosis of Primary Central Nervous System Lymphoma

NCT00226304
View directory record Official record
Conditions
HIV Infections, Lymphoma, AIDS-Related
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 26, 2026, 5:30 AM EDT
Completed Phase 4 Interventional

QUALITE Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection

NCT00232908
View directory record Official record
Conditions
HIV Infections
Interventions
ARV regimen, enfuvirtide [Fuzeon]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
103
States / cities
Phoenix, Arizona • Bakersfield, California • Berkeley, California + 78 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 26, 2026, 5:30 AM EDT
Completed Phase 2 Interventional Results available

Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)

NCT03272347
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Islatravir, Placebo to Islatravir, Doravirine, Placebo to Doravirine, Lamivudine, Placebo to Lamivudine, Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate, Placebo to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate, Doravirine/Islatravir
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
10
States / cities
Phoenix, Arizona • Sacramento, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Oct 26, 2026, 5:30 AM EDT